First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (FLIPPER)

Share this content:
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (FLIPPER)

Sponsors and Collaborators
iOMEDICO AG
Glaxo SmithKline

Contact
Oliver Rieder, PhD
0049 761 15242 ext 0
info@iomedico.com

Principal Investigator
Michael Staehler, PD MD, Ludwig-Maximilians-Universität München, Klinikum Grosshadern

ClinicalTrials.gov Identifier
NCT01521715

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters